RCKT · Rocket Pharmaceuticals, Inc.
Market Cap
$423.73M
Shares
109.77M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Christopher Stevens | Chief Operating Officer | $3,555,467 |
| Gaurav Shah | Chief Executive Officer | $3,510,241 |
| Martin Wilson | General Counsel and Chief Corporate Officer, Senior Vice President, Interim Principal Financial Officer | $3,397,880 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Gaurav Shah | Chief Executive Officer | $6,841,407 |
| Kinnari Patel | Pharm.D., MBA President, Head of R&D and Chief Operating Officer | $6,696,055 |
| Aaron Ondrey | Chief Financial Officer, Principal Financial Officer | $2,989,763 |
| Jonathan Schwartz | Chief Medical and Gene Therapy Officer | $2,364,309 |
| Martin Wilson | General Counsel and Chief Corporate Officer, Senior VP | $2,113,954 |
| John Militello | Principal Accounting Officer and Former Interim Principal Financial Officer, Vice President | $1,175,588 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Gaurav Shah | Chief Executive Officer | $8,013,553 |
| Kinnari Patel | Pharm.D., MBA President, Head of R&D and Chief Operating Officer | $4,846,102 |
| Jonathan Schwartz | Chief Medical and Gene Therapy Officer | $3,157,844 |
| John Militello | Principal Accounting Officer and Former Interim Principal Financial Officer, Vice President | $1,527,570 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Gaurav Shah | Chief Executive Officer | $6,553,203 |
| Kinnari Patel | Pharm.D., MBA President, Head of R&D and Chief Operating Officer | $4,516,885 |
| Mayo Pujols | Chief Technical Officer, Executive Vice President | $3,149,702 |
| Raj Prabhakar | Chief Business Officer, Senior Vice President | $2,819,120 |
| Jonathan Schwartz | Chief Medical and Gene Therapy Officer | $2,532,457 |
| John Militello | Principal Accounting Officer and Interim Principal Financial Officer, Vice President | $1,751,386 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Gaurav Shah | Chief Executive Officer | $7,918,750 |
| Carlos Garcia-Parada | Former Chief Financial Officer and Principal Financial Officer | $5,693,840 |
| Kinnari Patel | Pharm.D., MBA President and Chief Operating Officer | $5,257,422 |
| Jonathan Schwartz | Chief Medical and Gene Therapy Officer | $1,881,845 |
| Martin Wilson | General Counsel and Chief Compliance Officer, SVP | $1,560,950 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Gaurav Shah | Chief Executive Officer | $6,859,135 |
| Kinnari Patel | Pharm.D., MBA President and Chief Operating Officer | $4,080,621 |
| Jonathan Schwartz | M.D., SVP and Chief Medical Officer | $1,870,733 |
| Kamran Alam | Senior Vice President – Finance and Principal Financial Officer | $634,250 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Gaurav Shah | Chief Executive Officer | $3,883,646 |
| Kinnari Patel | Pharm.D., MBA President and Chief Operating Officer | $2,776,209 |
| Kamran Alam | Senior Vice President – Finance and Principal Financial Officer | $2,051,457 |
| Jonathan Schwartz | M.D., SVP and Chief Medical Officer | $1,475,675 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Gaurav Shah | M.D. Chief Executive Officer | $6,375,752 |
| Kinnari Patel | Pharm.D., MBA President and Chief Operating Officer | $2,991,073 |
| Jonathan Schwartz | M.D., SVP and Chief Medical Officer | $1,356,675 |
Key facts
CIK
1281895
CUSIP
77313F106
13F (30d)
156 filings
155 filers
Visit website
Investor relations